U.S. Immunology Treaters Resistant to Switching Stable Humira Patients to Biosimilars, According to Spherix Global Insights

Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and practices. EXTON, Pa., June 7, 2023 /PRNewswire/ — Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according to the latest findings from Spherix Global Insights, even the first to market advantage can’t … Read more

Genentech’s Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights

Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s 8mg aflibercept potentially around the corner. EXTON, Pa., June 7, 2023 /PRNewswire/ — Genentech’s Vabysmo got an 18-month head start over Regeneron’s high dose Eylea (8mg aflibercept), but that lead time may be coming to … Read more

The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights

New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 /PRNewswire/ — The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S. Despite the significant size and unmet need of the potential market, pharmaceutical companies have yet to capitalize on … Read more